HIV

Cat. No.

A30221

CAS No.

139339-45-0

Ro24-7429

Ro24-7429 is a potent antagonist of the HIV-1 transactivator protein Tat, functioning primarily to inhibit Tat-mediated transcriptional activation. Additionally, Ro24-7429 acts as a runt-related transcription factor 1 (RUNX1) inhibitor. This compound exhibits significant biological activities, including anti-HIV, antifibrotic, and anti-inflammatory effects, making it a valuable tool for research applications in virology, fibrosis, and inflammation.

Cat. No.

A51277

CAS No.

153021-75-1

Trecovirsen

Synonyms: GEM91

Trecovirsen is an antiviral agent that targets HIV gag mRNA by hybridizing with its complementary sequence at the initiation site. This interaction leads to the induction of a reversible, dose-dependent prolongation of activated partial thromboplastin time due to its polyanionic properties. Trecovirsen is applicable for research on HIV infection, providing insights into the mechanisms of viral replication and potential therapeutic strategies.

Cat. No.

A51348

CAS No.

2411819-82-2

NBD-14270

NBD-14270 is a potent HIV-1 entry antagonist that specifically targets the gp120 protein of the virus. With an IC50 of 180 nM, it exhibits significant antiviral activity against various HIV-1 Env-pseudotyped virus strains. Additionally, NBD-14270 demonstrates low cytotoxicity, with a CC50 exceeding 100 μM, making it a valuable candidate for research applications in HIV-1 inhibition.

Cat. No.

A51385

CAS No.

2234273-72-2

NBD-14189

NBD-14189 is a potent HIV-1 entry antagonist that demonstrates an IC50 of 89 nM against the HIV-1 HXB2 pseudovirus. This compound targets the HIV-1 gp120 protein, effectively inhibiting viral entry and showcasing notable antiviral activity with an EC50 of less than 200 nM. NBD-14189 is suitable for research applications focusing on HIV-1 entry mechanisms and antiviral drug development.

Cat. No.

A51487

CAS No.

2919019-36-4

HIV-1 inhibitor-64

HIV-1 inhibitor-64 (Compound 7c) is a potent antagonist targeting HIV-1, demonstrating effective inhibition of both wild-type and resistant mutants, specifically E138K/Q148K and G140S/Q148R, with EC50 values of 62.5 nM and 11.3 nM, respectively. This compound exhibits significant antiviral activity, making it a valuable tool for AIDS research and studies focused on HIV-1 resistance mechanisms.

Cat. No.

A51792

CAS No.

716354-04-0

GSK163929

GSK163929 is an orally bioavailable CCR5 antagonist, primarily targeting HIV infection. This compound demonstrates anti-HIV activity by inhibiting the CCR5 co-receptor, crucial for viral entry into host cells. GSK163929 has been evaluated for safety, showing no adverse effects in rat and dog models at specified dosages. Its properties make it a valuable tool for research in HIV therapies and co-receptor interaction studies.

Cat. No.

A51814

CAS No.

1097732-62-1

KRH-3955

KRH-3955 is a potent CXCR4 antagonist that demonstrates significant anti-HIV-1 activity, particularly against X4 strains. It effectively inhibits the replication of various X4 HIV-1 clinical isolates and is active against recombinant strains with resistance mutations in reverse transcriptase, protease, and tyrosinase. KRH-3955 disrupts the binding of SDF-1alpha to CXCR4, thereby interfering with calcium signaling through this receptor, along with inhibiting antibody binding to CXCR4. With an oral bioavailability of 25.6% in rats, KRH-3955 has shown efficacy in vivo, making it a valuable tool for HIV research.